Entries Invited for 1997 Rose Kushner Writing Awards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 1
Volume 6
Issue 1

BETHESDA, Md--The American Medical Writers Association is accepting applications for the 1997 Rose Kushner Awards for Writing Achievement in the Field of Breast Cancer. A cash award of $1,000 for the winning entry in each of five categories will be provided through a grant from Zeneca Pharmaceuticals.

BETHESDA, Md--The American Medical Writers Association is acceptingapplications for the 1997 Rose Kushner Awards for Writing Achievement inthe Field of Breast Cancer. A cash award of $1,000 for the winning entryin each of five categories will be provided through a grant from ZenecaPharmaceuticals.

The awards were established in 1990 as a memorial tribute to Rose R.Kushner, a former member of the Association and a pioneer in breast cancereducation and patient advocacy. A survivor of breast cancer for 16 years,Rose Kushner died on January 7, 1990, at the age of 60.

Award categories include published lay articles (newspapers or magazines),published scientific articles (journals), brochures and monographs, books(medical and lay audiences), and scripts for video, film, or radio (medicaland lay audi-ences). Entries must have been published or shown from March1996 through March 1997.

The competition is open to AMWA and non-AMWA members. Entries may besubmitted by persons other than the writer, but the award, presented atthe AMWA Annual Conference, goes only to the writer.

The deadline for entries is May 10, 1997. For more information, contactthe American Medical Writers Association, 9650 Rockville Pike, Bethesda,MD 20814-3998. Telephone: 301-493-0003; Fax: 301-493-6384.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.